Evaluation of the kinetic and relaxation time of gentamicin sulfate released from hybrid biomaterial Bioglass-chitosan scaffolds. Applied Surface Science, Elsevier, 2015, 353, pp.200-208 SEM observations allowed understanding the bond between the glass grains and the chitosan matrix. In vitro results showed that scaffolds form a hydroxyapatite (HA) Ca 10 (PO 4 ) 6 (OH) 2 after 15 days of immersion in a simulated body fluid (SBF).
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Introduction
Bone loss or failure resulting from a disease or an accident is an important problem in the health field. In the maxillofacial and orthopedic surgery, metal prosthesis, ceramics and other synthetic biomaterials are widely used to bone repair. Nowadays, tissue engineering promises alternative approaches to repair the loss or malfunction of a tissue or an organ [1] . Indeed, a lot of porous scaffolds synthesized with different biodegradable polymers have been fabricated and used for tissue engineering of liver [2] , nerve [3] and bone [4] . Natural polymers already have been studied using lyophilization method [5] : alginate [6] , collagen and other synthetic polymers as polyvinyl alcohol [7] . Chitosan (figure 1) presents important biological characteristics as biocompatibility, biodegradability, non-toxicity, affinity to proteins, antibacterial, antitumoral properties [8] [9] [10] . It used for a lot of medical applications as sutures, bone substitutes and drug delivery [11] . In contrast to all other biodegradable polymers, chitosan is the only one exhibiting a cationic character rendering it unique among all others. The cationic character being based on its primary amino groups is responsible for various properties and subsequently for its use in drug delivery systems [12] . Studied scaffolds were reinforced by the bioactive glass 46S6. This glass can create a hydroxyapatite layer on its surface when it is immersed in SBF [13] [14] and allow creating an intimate bond with the bone tissue. In a previous study, the comparison of the behavior of pure glass and composite glass chitosan highlighted the effects of chitosan on the kinetic of chemical reactivity and bioactivity. The advantages of the novel structure of hybrid biomaterial 46S6-chitosan lead to the acceleration of the two parameters compared to pure glass 46S6 [14] . Gentamicin-sulfate (figure 2) was combined with these hybrid biomaterials because it is active against Staphylococcus aureus responsible for osteomyelitis [15] [16] . Gentamicin sulfate belong aminoglycoside class of bactericidal antibiotic [17] . The use of antibiotic delivery M a n u s c r i p t 3 systems for treatment of bone infection is a subject in full development. The poor circulation of blood in the osseous tissue makes necessary the supply of great amount of antibiotics to reach the adequate therapeutic level in the affected region. These systems allow the release by diffusion of an antibiotic through a biodegradable polymer matrix [18] [19] [20] [21] . Some studies showed that different stimuli as temperature or pH [18] involve the release of the drug [22] [23] [24] [25] . The present study gives special attentions to:
i) The synthesis of chitosan/bioactive glass/gentamicin sulfate scaffolds and their physicochemical characterizations;
ii) The modifications on the surface of scaffolds after immersion in SBF and the controlled release of gentamicin sulfate evaluated by UV-spectrophotometry.
iii) The elaboration of mathematic models and the interpretation of the time of relaxation concerning the release of gentamicin sulfate.
Materials and methods

Preparation of scaffolds
The synthesis of scaffolds is divided in three main steps (figure 3).
First, the bioactive glass 46S6 was prepared from sodium metasilicate (Na 2 SiO 3 ), silicon oxide (SiO 2 ), calcium metasilicate (CaSiO 3 ) and sodium metaphosphate (Na 3 P 3 O 9 ). It is composed of 46% of SiO 2 , 24% of CaO, 24% of Na 2 O and 6% of P 2 O 5 . It was synthesized by the melting process as described in a previous work [26] . Obtained glasses were grinded and sift to obtain a fine granulometry less than 40 m. The second step has consisted to dissolve 3 g of chitosan powder, with a medium molecular weight, in acetic acid solution 1% v/v. The solution was stirred under magnetic stirring at room temperature during 24 hours in order to dissolve all the M a n u s c r i p t 4 chitosan powder. The final step is the preparation of three scaffolds: 2CH-1BG, 1CH-1BG and 1CH-2BG presenting different ratios chitosan/glass (CH/BG) (table 1). The glass was added in the chitosan solution. The mixtures were homogenized for 24 hours in an ultrasonic bath. To elaborate scaffolds with gentamicin sulfate, the antibiotic was added in the mixtures. In this work, scaffolds were synthesized with 1% w/v and 3% w/v of gentamicin sulfate. These concentrations have been chosen to avoid reaching the threshold of toxicity of gentamicin sulfate. Indeed, it can be highly nephrotoxic, particularly if multiple doses accumulate during treatment.
Once the homogenization of chitosan/bioactive glass/gentamicin sulfate completed, the solutions were cast into well-plates. They were frozen at -20°C for all-night to frozen the core of the material and placed in a freeze-dryer at 0.65 mbar at -60°C during 24 hours to remove all solvents in samples. Obtained scaffolds were washed in a NaOH solution 0.4% w/v and distilled water to eliminate traces of acetic acid. They were frozen and lyophilized as previously stated.
Finally, scaffolds of 13 mm of diameter were obtained with different amounts of chitosan and bioactive glass.
In vitro evaluation of the bioactivity
In vitro assays, as described in a previous work [14] , were realized in a SBF whose the chemical composition is similar to the blood plasma (table 2) [14, 27] . 
In vitro study of the release of gentamicin sulfate
The controlled release of gentamicin sulfate was studied after immersion of scaffolds of 300 mg (±5 mg) in 10 mL of a physiological saline solution (BioWhittaker ® Dulbecco's PBS) without calcium and magnesium to avoid the chemical reaction of bioactivity. Its buffering capacity is based on the dihydrogen/hydrogen pair which is also one of three major mechanisms for maintaining blood pH:
The release of gentamicin sulfate was studied after 5, 10, 20, 30 minutes and 1, 2, 6 hours in triplicate. These notices were chosen because some studies have proved that gentamicin sulfate is released quickly [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . PBS solutions were analyzed at 256 nm using UV spectrophotometer (Jenway 6705) to measure the concentration of gentamicin sulfate. The blank control is 10 mL of PBS without materials and the calibration curve was plotted using standards solutions of increasing concentrations of gentamicin sulfate from 1 to 30 mg.mL -1 . The results were averaged with standard deviation. 3 .g -1 of pore volume. It was found that the specific surface area and pore volume increase when the introduced content of chitosan increases [14] . Moreover, specific surface area of 46S6 and chitosan are respectively 0.9 and 0.7 m².g -1 [14] . The association of chitosan with the bioactive glass 46S6 increases the specific surface area. Furthermore, with a high content of chitosan, the average pore diameter also increases. Indeed, 2CH-1BG scaffolds present an average pore diameter of 5.2 nm, 1CH-1BG 3.6 nm and 1CH-2BG 4.0 nm.
Results and discussions
Surface characterizations of scaffolds
SEM observations were performed using a Jeol JSM 6301F scanning electron microscope. The surfaces of scaffolds before immersion in the SBF were registered. For all scaffolds, pores are -2CH-1BG scaffolds possess a wide variety of pores (fine and ample pores), that explains why they have a pore volume and an average pore diameter larger than the other two.
-1CH-1BG scaffolds present the same morphology of pores compared to 2CH-1BG scaffolds but they have a less homogeneous surface.
-1CH-2BG scaffolds have a more homogeneous surface but they present wider pores, this could explain an average pore diameter greater than 1CH-1BG scaffolds but a smaller pore volume.
These observations clearly confirm the obtained results by adsorption of N 2 . These variations of porosity function of the ration CH/BG could expand the capacity of uses of these biomaterials for medical applications.
Characterizations of scaffolds after in vitro assays
The XRD patterns of 1CH-1BG, 1CH-2BG, and 2CH-1BG scaffolds after 30 days of immersion in the SBF are presented in figure 6 . Several references as 46S6, chitosan scaffolds before immersion were chosen to observe an eventual change in the structure [27] [28] [29] [30] [31] [32] . The hydroxyapatite was chosen as reference to present its eventual formation on materials. A halo of diffraction is observed for 2CH-1BG scaffolds between 15 and 25 (2 °) due to the high amount of chitosan. After 30 days of immersion in the SBF, the formation of hydroxyapatite is confirmed by the appearance of two peaks of diffraction: at 25.9 (2 °) corresponding to the (002) apatite reflection and 31.8 (2 °) corresponding to the (211) apatite reflection [33] . For all the scaffolds, the bioactivity is observed from 15 days of immersion. Therefore, the content of 46S6 M a n u s c r i p t A c c e p t e d M a n u s c r i p t
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The originality of these materials is that they can be elaborated with a drug in order to treat locally an infection. Scaffolds have been charged with gentamicin sulfate and the study of the release of this drug was undertaken.
Kinetic of the controlled release of gentamicin sulfate
Local antibiotic therapy has been already used in all types of bone infections. The aim of this investigation was to study the effect of the content of chitosan and bioactive glass on the kinetic of release of gentamicin sulfate.
The curves of release of gentamicin sulfate present same appearance (figure 10.a and 10.b):
Mathematical relations (table 5 and The release of gentamicin sulfate, in the PBS solution, follows a law of the type:
Where: C g is the gentamicin sulfate concentration, C 0 is the gentamicin sulfate limit concentration, t the immersion time and the relaxation time of the system. For scaffolds doped with 1% of gentamicin sulfate ( figure 10.a) , the release is fast up to 60 minutes of immersion. The gentamicin sulfate concentration goes from 0 to: 5.6 mg.mL -1 for 2CH-1BG, 3.7 mg.mL -1 for 1CH-1BG and 1.7 mg.mL -1 for 1CH-2BG. A stability of release is observed after 60 minutes. At 360 minutes, the concentration of gentamicin sulfate reaches 5.9 mg.mL -1 , 4.0 mg.mL -1 and 1.9 mg.mL -1 for respectively 2CH-1BG, 1CH-1BG and 1CH-2BG.
Concerning scaffolds doped with 3% of gentamicin sulfate (figure 10.b), the release also is fast up to 120 minutes. The concentration of gentamicin sulfate goes from 0 to: 11.9 mg.mL -1 for 2CH-1BG, 5.6 mg.mL -1 for 1CH-1BG and 1CH-2BG scaffolds. After 120 minutes, a stability of release is observed and the concentration of gentamicin sulfate reaches 12.3 mg.mL -1 for 2CH-1BG, 6.5 mg.mL -1 for 1CH-1BG and 1CH-2BG scaffolds.
A difference of a factor 2 is observed between the data of concentration of gentamicin sulfate for scaffolds with 1% of gentamicin sulfate and them with 3% of gentamicin sulfate. Several characteristics of scaffolds can explain the delivery of gentamicin sulfate such as their porosity and their specific area [13] . Indeed, 2CH-1BG scaffolds, having a larger specific surface area (7.9 m².g -1 ) and a larger pore volume (8.1 mm 3 .g -1 ), release more gentamicin sulfate (with either 1 or 3%) than the two other types of scaffolds; followed by 1CH-1BG scaffolds and 1CH-2BG
scaffolds. It has also been reported in several studies that the nature of the antibiotic were involved in the kinetics of release [13] . Indeed, the gentamicin sulfate presents an early release due to its hydrophilic character [13] .
For all scaffolds, the variations of the content of bioactive glass and that of chitosan do not impact the relaxation time. In contrast, the concentration of gentamicin sulfate increases the M a n u s c r i p t 
Conclusions
Porous CH-BG scaffolds were developed for use in bone tissue engineering applications. The antibiotic gentamicin sulfate was entrapped into the scaffolds via the freeze-drying method to M a n u s c r i p t • The concentration of gentamicin sulfate has an influence on the relaxation time of scaffolds.
• An increasing concentration of gentamicin sulfate delays the return to a new equilibrium. Table 6 : Laws of kinetics for scaffolds with 3% of gentamicin
